Costs associated with symptomatic systolic heart failure

PharmacoEconomics

Volumn 16, Issue 4, 1999, Pages 399-407

  Davey, Peter G ^a   Clarkson, Peter B M ^a   McMahon, Alex ^a   MacDonald, Thomas M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DOPPLER ECHOCARDIOGRAPHY; HEALTH CARE COST; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HOSPITAL COST; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SOCIAL SUPPORT; SYSTOLE; TWO DIMENSIONAL ECHOCARDIOGRAPHY; UNITED KINGDOM;

CROSS-SECTIONAL STUDIES; HEALTH CARE COSTS; HEART FAILURE, CONGESTIVE; HUMANS; SEVERITY OF ILLNESS INDEX; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0032727954     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199916040-00007     Document Type: Article

References (21)

1. Wheeldon NM, MacDonald TM, Flucker CJ, et al. Echocardiography in chronic heart failure in the community. Q J Med 1993; 86: 17-23
2. McDonagh TA, Morrison CE, Lawrence A, et al, Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997; 350: 829-33
3. The SOLVD Investigators, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure, N Engl J Med 1991; 325 (5): 293-302
4. The CONCENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316 (23): 1429-34
5. Applefeld MM. Chrome congestive heart failure where have we been? Where are we heading? Am I Med 1986; 80: 73-7
6. Johnstone D, Limacher M, Rousseau M. Clinical characteristics of patients in studies of left ventricular dysfunction. Am J Cardiol 1992; 70: 894-900
7. Parameshwar J, Poole-Wilson PA, Sutton GC Heart failure in a district general hospital. J R Coll Physicians Lond 1993; 26: 139-42
8. McMurray J, Hart W, Rhodes G. An evaluation of the cost of heart failure to the National Health Service in the UK. Br J Med Econ 1993; 6: 99-110
9. van Hout BA, Wielink G, Bonsel GJ, et al. Effects of ACE inhibitors on heart failure in The Netherlands: a pharmaco-economic model. Pharmacoeconomics 1993; 3: 387-97
10. Le Pen C, Levy K. Bonte J. Cost-effectiveness of captopril therapy after myocardial infarction. Arch Mal Coeur Vaiss 1994; 87:775-81
11. McMurray J. Davie A. The pharmacoeconomics of ACE inhibitors in chronic heart failure. Pharmaeocconomics 1996; 9188-97
12. Scott WG, Scott HM. Heart failure: a decision analytic analysis of New Zealand data using the published results of the SOLVD treatment trial. Pharmacoeconomics 1996; 9 (2): 156-67
13. Hummel S, Piercy J, Wright R, et al. An economic analysis of the Survival and Ventricular Enlargement (SAVE) study. Pharmacoeconomics 1997; 12(2Pt 1): 182-92
14. McMurray J, Davie A. The pharmacoeconomics of ACE inhibitors in chronic heart failure. Pharmacoeconomics 1996; 9 (3): 188-97
15. Coyle D, Faienza B, Jacobs P, et al. A guidance document for the costing process, 1 ed. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment, 1996
16. Jacobs P, Baladi J-F. Biases in cost measurement for economic evaluation studies in health care. Health Econ 1996; 5 (6): 525-9
17. Drummond M. Cost-of-illness studies: a major headache? Pharmacoeconomics 1992; 2: 1-4
18. Fleg JL, Kitzman DW, Aronow WS, et al. Physician management of patients with heart failure and normal versus decreased left ventricular systolic function. Am J Cardiol 1998; 81: 506-9
19. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991; 3 (I); 951-7
20. Davie AP, Francis CM, Caruana L, et al. Assessing diagnosis in heart failure; which features are any use? Q J Med 1997; 90: 335-9
21. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13